IP Verse

Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity - EP2501384

The patent EP2501384 was granted to Novartis on Nov 1, 2023. The application was originally filed on Nov 17, 2010 under application number EP10781781A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2501384

NOVARTIS
Application Number
EP10781781A
Filing Date
Nov 17, 2010
Status
Patent Maintained As Amended
Sep 29, 2023
Publication Date
Nov 1, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKNov 17, 2016ELKINGTON AND FIFEADMISSIBLE
HAMM & WITTKOPPNov 17, 2016HAMM & WITTKOPPADMISSIBLE
INTAS PHARMACEUTICALSNov 17, 2016ISARPATENTADMISSIBLE
TEVA PHARMACEUTICALSNov 17, 2016D YOUNGADMISSIBLE
FRESENIUS KABI DEUTSCHLANDNov 14, 2016FRESENIUS KABI DEUTSCHLANDADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP1533304
DESCRIPTIONWO2004005281
DESCRIPTIONWO2007015870
DESCRIPTIONWO2007015871
DESCRIPTIONWO2008037716
INTERNATIONAL-SEARCH-REPORTWO2004005281
INTERNATIONAL-SEARCH-REPORTWO2006119154
OPPOSITIONWO2004005281
OPPOSITIONWO2006119154
OPPOSITIONWO2008037716

Non-Patent Literature (NPL) Citations (55) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Yady Manrique ET AL, "Crushed Tablets: Does the Administration of Food Vehicles and Thickened Fluids to Aid Medication Swallowing Alter Drug Release?", J Pharm Pharm Sci, (20140501), pages 207 - 219, URL: http://eprints.qut.edu.au/71945/1/21020-54199-1-PB_Crushing.pdf, (20140603), XP055121285
EXAMINATION- Robert G. Strickley ET AL, "Pediatric drugs-a review of commercially available oral formulations", Journal of Pharmaceutical Sciences, (20080501), vol. 97, no. 5, doi:10.1002/jps.21101, ISSN 0022-3549, pages 1731 - 1774, XP055121290
EXAMINATION- Ophelia Q. P. Yin ET AL, "Effects of Yogurt and Applesauce on the Oral Bioavailability of Nilotinib in Healthy Volunteers", The Journal of Clinical Pharmacology, (20111101), vol. 51, no. 11, doi:10.1177/0091270010384116, ISSN 0091-2700, pages 1580 - 1586, XP055121223
OPPOSITION- #9 Pharmacotherapy, (20010000), vol. 21, no. 10, page 1288
OPPOSITION- A F Isles Et Al, "Bioavaiability of Somophyllin-CRT capsules", Br.J.Clin.Pract., (19840000), vol. 35, pages 68 - 70, XP055344668
OPPOSITION- Bladh N et al, "A New Esomeprazole Packet (Sachet) Formulation for Suspension: In Vitro Characteristics and Comparative Pharmacokinetics Versus Intact Capsules/Tablets in Healthy Volunteers", Clinical Therapeutics, (20070000), vol. 29, no. 4, pages 640 - 649, XP027153109
OPPOSITION- CAROLYN SIMPSONS et al., Rx: Reading and Following the Directions for all Kinds of Medication, New York, The Lifeskills Library, (19940000), pages 42 - 43, XP055326443
OPPOSITION- Chapter 10, Chapter 10, VICKI NIBLETT, A Nurse's Guide to Dosage Calculation: Giving Medications Safely, Lippincott Williams & Wilkins, (20060000), pages 127 - 131, XP055326437
OPPOSITION- "Chapter 91", MARY ANNE KODA-KIMBLE et al., Handbook of Applied Therapeutics. 8th ed., Lippincott Williams Wilkins, (20050000), XP055326448
OPPOSITION- Consultant Pharmacist, (20090000), vol. 24, no. 10, page 746
OPPOSITION- C. TANAKA et al., "Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL", J. CLIN. ONCOL. 2006 ASCO ANNUAL MEETING PROCEEDINGS PART. I, (20060000), vol. 24, no. 18S, page 3095, XP009144277
OPPOSITION- Effexor XR PIL, (20080000), pages 1 - 51, XP055328338
OPPOSITION- Embeda capsules PIL, (20090000), XP055327816
OPPOSITION- "Esomeprazole magnesium DR capsules; patient information leaflet;", Esomeprazole magnesium DR capsules; patient information leaflet;, (20060000), pages 1 - 37, XP055327779
OPPOSITION- European Medicines Agency (EMA), "Tasigna® - Scientific Discussion", EMEA/161203/2009, (20070327), pages 1 - 10, URL: http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500005412.pdf, XP055324489
OPPOSITION- FDA, "Food-effect Bioavailability and Fed Bioequivalence Studies", Guidance for Industry, (20021200), URL: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf, XP008138108
OPPOSITION- "HIGHLIGHT OF PRESCRIBING INFORMATION", Colazal PIL, (20070000), XP055329210
OPPOSITION- "HIGHLIGHT OF PRESCRIBING INFORMATION", Depakote sprinkle PIL, (20090000), XP055329206
OPPOSITION- "HIGHLIGHT OF PRESCRIBING INFORMATION", Focalin XR PIL, (20090000), XP055329211
OPPOSITION- "HIGHLIGHT OF PRESCRIBING INFORMATION", Prevacid PIL, (20090000), XP055329215
OPPOSITION- I-Der Lee et al, "Effects on the Pharmacokinetics and Pharmacodynamics in the Elderly of Coadministering Ramipril with Water, Apple Juice, and Applesauce", Pharm. Res., (19960000), vol. 13, no. 4, pages 639 - 42, XP055344681
OPPOSITION- I-Der Lee Et Al, "Stability of ramipril in water, apple juice, and applesauce", Am. J. Health Syst. Pharm., (19950000), vol. 52, no. 21, pages 2433 - 36, XP055344681
OPPOSITION- J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings part. I, (20060000), vol. 24, no. 18s, page 3095
OPPOSITION- Journal of Clinical Pharmacology, (20100000), vol. 50, no. 9, page 1089
OPPOSITION- J Pharm Pharm Sci, pages 207 - 219
OPPOSITION- Katrin Witschital Et Al, "Pharmakokinetik von Theophyllin in einer Retardformulierung bei jugendlichen Asthmatikern", Arzneimittel-Forschung, (19980000), vol. 48, no. 5a, pages 593 - 596, XP055344663
OPPOSITION- "Methylphenidate HCI XR Capsules; patient information leaflet;", Methylphenidate HCI XR Capsules; patient information leaflet;, (20090400), pages 1 - 22, XP055327785
OPPOSITION- Montelukast sodium PIL, (20080000), XP055328331
OPPOSITION- "Morphine sulfate extended-release capsules; patient information leaflet;", Morphine sulfate extended-release capsules; patient information leaflet;, (20070300), pages 1 - 25, XP055327791
OPPOSITION- Proc.Am.Soc.Clin.Oncol., (19970000), vol. 16, no. 33, page 61 a
OPPOSITION- Rifampin, "Drug Information: Rifampin", Medline Plus, (20030000), URL: http://www.nlm.nih.qov/medlineplus/druqinfo/medmaster/a682403.html, XP055327809
OPPOSITION- "Sheik Hosenbocus MD , et al., A Review of Long-Acting Medications for ADHD in Canada", Journal of the Canadian Academy of Child and Adolescent Psychiatry, (20091100), vol. 18, no. 4, pages 331 - 339, XP055324471
OPPOSITION- "Summary of Product Characteristics", Tasigna, (20070000), pages 1 - 50, XP055327738
OPPOSITION- "US FDA Draft Guidance on Diltiazem Hydrochloride", US FDA, (20080000), XP055329201
OPPOSITION- VAN ERP N P et al., "Clinical pharmacokinetics of tyrosine kinase inhibitors", CANCER TREATMENT REVIEWS, US, vol. 35, no. 8, ISSN 0305-7372, (20090905), pages 692 - 706, (20090905), XP026774941
OPPOSITION- van Erp N P et al, "Clinical pharmacokinetics of tyrosine kinase inhibitors", Cancer Treatment Reviews, US, vol. 35, no. 8, pages 692 - 706, XP026774941
OPPOSITION- YIN O et al., "EFFECT OF YOGURT AND APPLESAUCE ON THE ORAL BIOVAILABILITY OF NILOTINIB IN HEALTHY SUBJECTS", JOURNAL OF CLINICAL PHARMACOLOGY, HAGERSTOWN, MD , US, (20100901), vol. 50, no. 9, ISSN 0091-2700, page 1089, XP009144158
OPPOSITION- Robert G Strickley et al, "Pediatric drugs-a review of commercially available oral formulations", Journal of Pharmaceutical Sciences, (20080000), vol. 97, no. 5, pages 1731 - 1774, XP055121290
OPPOSITION- ROBERT G. STRICKLEY et al., "Pediatric Drugs - A Review of Commercially Available Oral Formulations", Journal of Pharmaceutical Sciences, (20080500), vol. 97, no. 5, pages 1731 - 1773, XP055121290
OPPOSITION- WEISBERG E et al., "Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl", Cancer Cell ., (20050200), vol. 7, no. 2, pages 129 - 141, XP002489105
OPPOSITION- "444 Management of Anatomic Hilar Variations During Laparoscopic Right Hepatectomy", Gastroenterology, Chicago, IL , United States ., (20090530), vol. 136, no. 5 Suppl., page A444, XP026114560
OPPOSITION- Lise Eliot et al, "Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation", Clinical Therapeutics, (20020000), vol. 24, no. 2, pages 260 - 268, XP055344655
OPPOSITION- WELLS KA et al., "In vitro stability, potency, and dissolution of duloxetine enteric- coated pellets after exposure to applesauce, apple juice, and chocolate pudding;", Clin Ther., (20080000), vol. 30, no. 7, pages 1300 - 1308, XP023612209
OPPOSITION- Wells Kevin A et al, "In vitro stability, potency, and dissolution of duloxetine enteric-coated pellets after exposure to applesauce, apple juice, and chocolate pudding", Clinical Therapeutics, (20080000), vol. 30, no. 7, pages 1300 - 1308, XP023612209
OPPOSITION- ANAND SISTLA et al., "Powder-in-Bottle Formulation of SU 011248. Enabling Rapid Progression into Human Clinical Trials", Drug Development and Industrial Pharmacy, (20040102), vol. 30, no. 1, pages 19 - 25, XP055324473
OPPOSITION- HAZARIKA MAITREYEE et al., "Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 SEP 2008 LNKD- PUBMED:18765523, (20080901), vol. 14, no. 17, ISSN 1078-0432, pages 5325 - 5331, XP002621031
OPPOSITION- MAITREYEE HAZARIKA et al., "Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome - Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib", Clinical Cancer Research, (20080900), vol. 14, no. 17, pages 5325 - 5331, XP002621031
OPPOSITION- Maitreyee Hazarika et al., "Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib", Clinical Cancer Research, (20080901), vol. 14, no. 17, pages 5325 - 5331, XP002621031
OPPOSITION- Yin Ophelia Q P et al, "Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants", JOURNAL OF CLINICAL PHARMACOLOGY, (20100000), vol. 50, no. 2, pages 188 - 194, XP009144100
OPPOSITION- YIN OPHELIA Q P et al., "Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants", JOURNAL OF CLINICAL PHARMACOLOGY, HAGERSTOWN. MD , US, (20100201), vol. 50, no. 2, ISSN 0091-2700, pages 188 - 194, XP009144100
OPPOSITION- Ophelia Q P Yin et al, "Effects of Yogurt and Applesauce on the Oral Bioavailability of Nilotinib in Healthy Volunteers", The Journal of Clinical Pharmacology, (20110000), vol. 51, no. 11, pages 1580 - 1586, XP055121223
OPPOSITION- MARTIN A. CHAMPAGNE et al., "Imatinib mesylate (ST1571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study", Blood, (20040701), vol. 104, no. 9, pages 2655 - 2660, XP055324466
OPPOSITION- FARIBA NAVID et al., "Stability of Sunitinib in Oral Suspension", The Annals of Pharmacotherapy, (20080700), vol. 42, no. 7, pages 962 - 966, XP008101835
OPPOSITION- Broomhead Alan et al, "Comparative Bioavailability of Sustained-Release Morphine Sulfate Capsules versus Pellets", Clinical Drug Investigation, (19970000), vol. 14, no. 2, pages 137 - 145, XP055344658
OPPOSITION- Tommy Andersson et al, "Esomeprazole 40mg Capsules are Bioequivalent when Administered Intact or as the Contents Mixed with Applesauce", Clinical Drug Investigation, (20010000), vol. 21, no. 1, pages 67 - 71, XP055344652

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents